Novel Tubeimoside I liposomal drug delivery system in combination with gemcitabine for the treatment of pancreatic cancer.

Aim: To evaluate the anti-pancreatic cancer effect of novel Tubeimoside I multifunctional liposomes combined with gemcitabine. Methods: Liposomes were prepared through the thin film hydration method, with evaluations conducted on parameters including encapsulation efficiency (EE%), particle size, polydispersity index (PDI), zeta potential (ZP), storage stability, and release over a 7-day period. The cellular uptake rate, therapeutic efficacy in vitro and in vivo and the role of immune microenvironment modulation were evaluated. Results: The novel Tubeimoside I multifunctional liposomal exhibited good stability, significant anti-cancer activity, and immune microenvironment remodeling effects. Furthermore, it showed a safety profile. Conclusion: This study underscores the potential of Novel Tubeimoside I multifunctional liposomal as a promising treatment option for pancreatic cancer. Article highlights Tubeimoside I was used instead of cholesterol as the membrane component of liposomes. Tubeimoside I can not only be used as a membrane stabilizer, but also as a chemotherapy adjuvant. Tubeimoside I and gemcitabine have synergistic anti-cancer effects. Tub I-GEM-LPs can reconstruct the immune microenvironment. Tub I-GEM-LPs can improve the hemolysis of Tub I. Tub I-GEM-LPs efficiently promoted tumor cell apoptosis. Tub I-GEM-LPs has better stability and significantly reduced drug leakage rate. These Tub I-GEM-LPs may aid in the treatment of pancreatic cancer. [ABSTRACT FROM AUTHOR]